News

2020 October 14: Katairo announces "Enrolement completed" in STARTT study of Remofuscin

2019 June 26: Katairo announces "First Patient Treated" in STARTT  study of Remofuscin

2019 June 06 Patientinformation STARTT study Nijmegen and Leiden

2019 May 20 PatientInformation STARTT study Tuebingen

2019 May 20 PatientInformation STARTT study Southampton

2018 February 14: Stargardt-Krankheit: 6 Millionen für klinische Studie (German)

2018 February 09: Katairo receives funding for STGD POC study

2017 March 25: Katairo licenses IP rights and data from Takeda

Although Katairo is preparing a phase 2 trial for Stargardt disease, it is still too early to contact the company or its partners for more details. If you are interested in receiving up-to-date information by e-mail, please register for Katairo's newsletter below.

For the purpose of being contacted by Katairo upon important news, you may provide your e-mail contact information below.

By subscribing to the newsletter, you consent to the use and storage of your data described here and in our privacy policy.

We will not forward your contact information to any third party unless necessary for storing or sending e-mails to you with our newsletter service provider within the limitations of our privacy policy.  We will store your data until you tell us otherwise or until this newsletter is discontinued - of which we will notify you. A link to our privacy policy is provided at the bottom of the page.